Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 09, 2023

Liquid Biopsy Breast Cancer Methylation Assay for Predicting Early Disease Progression and Survival

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Clin. Cancer Res 2022 Dec 19;[EPub Ahead of Print], K Visvanathan, L Cope, MJ Fackler, M Considine, L Sokoll, LA Carey, A Forero-Torres, JN Ingle, NU Lin, R Nanda, AM Storniolo, S Tulac, N Venkatesan, NC Wu, S Marla, S Campbell, M Bates, CB Umbricht, AC Wolff, S Sukumar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading